Geographic Atrophy Secondary To Age Related Macular Degeneration — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for geographic atrophy secondary to age related macular degeneration. 6 active patents protecting 1 drugs from 0+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
6
Active US patents
70/100
Avg vulnerability
—
Annual revenue covered

Originators in Geographic Atrophy Secondary To Age Related Macular Degeneration

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating geographic atrophy secondary to age related macular degeneration. Each bar = one year. Y-axis scaled to peak year (3 patents).

1
26
2
27
3
34

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
AVACINCAPTAD PEGOL SODIUM — 6 70 — 2026-11-11

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8236773 AVACINCAPTAD PEGOL SODIUM method of use 88 2026-11-11
9617546 AVACINCAPTAD PEGOL SODIUM method of use 88 2027-02-14
12016875 AVACINCAPTAD PEGOL SODIUM method of use 75 2034-07-11
11491176 AVACINCAPTAD PEGOL SODIUM method of use 70 2034-07-11
11273171 AVACINCAPTAD PEGOL SODIUM method of use 70 2034-07-11
7579456 AVACINCAPTAD PEGOL SODIUM composition of matter 30 2027-02-14

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7579456 AVACINCAPTAD PEGOL SODIUM composition of matter 30 2027-02-14
11491176 AVACINCAPTAD PEGOL SODIUM method of use 70 2034-07-11
11273171 AVACINCAPTAD PEGOL SODIUM method of use 70 2034-07-11
12016875 AVACINCAPTAD PEGOL SODIUM method of use 75 2034-07-11
9617546 AVACINCAPTAD PEGOL SODIUM method of use 88 2027-02-14
8236773 AVACINCAPTAD PEGOL SODIUM method of use 88 2026-11-11

Related